ArticleHepatology communications2026
High incidence of advanced liver disease and mortality in patients presenting with alcohol use disorder.
Article in Hepatology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLittle is known about the long-term risk of developing cirrhosis in patients with alcohol use disorder (AUD).
methodsThis was a retrospective cohort of patients with AUD presenting to healthcare centers between January 2006 and June 2017. Individuals ≥18 years old with a diagnosis of AUD based on ICD-9 and ICD-10 codes were included. Patients with concurrent cirrhosis were excluded. Then, patients were followed until August 2021 for the development of complications or mortality.
resultsA total of 32,808 patients with AUD were included in the final analysis. During an average follow-up of 5.7 years, 12.3% of patients developed incident cirrhosis, and the overall mortality was 20.2%. The risk of cirrhosis increased in patients with diabetes mellitus (DM) [hazard ratio (HR), 1.52; 95% CI, 1.41-1.63; p<0.001] and hepatitis C (HR, 3.15; 95% CI, 2.93-3.39; p<0.001), whereas African American (AA) race had a protective effect (HR, 0.76; 95% CI, 0.7-0.82; p<0.001). Development of cirrhosis doubled the mortality rate (HR, 2.55; 95% CI, 2.39-2.72; p<0.001). The presence of DM, concomitant hepatitis C infection, and non-AA race collectively conferred a greater risk of cirrhosis and mortality in individuals with AUD.
interpretationPatients presenting with AUD are at high risk for developing incident cirrhosis and mortality. Concurrent DM and hepatitis C increase the risk of cirrhosis and mortality. Early intervention in patients presenting with AUD is urgently warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.